Tysabri and PML: What Florida Patients Should Know About Risk Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Communication to Specific Exposure Concerns

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. Recent clinical reports emphasize the importance of regular safety monitoring, including JC virus antibody testing and MRI surveillance. Building on decades of pharmacovigilance research, this page reviews current safety protocols and what Florida patients need to know.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal considerations regarding the statute of limitations for filing a claim, is essential. The clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri's mechanism of action involves blocking alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This immunosuppressive effect in the central nervous system creates an environment where JC virus can reactivate and cause PML. The mechanistic pathway is well-established: Tysabri reduces immune surveillance in the brain, allowing JC virus to replicate unchecked in oligodendrocytes, leading to demyelination and neuronal damage. The FDA-approved labeling for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is only available through a restricted distribution program called TOUCH, which requires prescribers to evaluate patients at specified intervals and report any cases of PML to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations: Statute of Limitations in Florida

From a risk perspective, the adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. While the boxed warning clearly states the risk, questions have arisen about whether prescribers and patients were adequately informed about the magnitude of risk and the specific factors that increase it. For affected patients in Florida, settlement-related considerations depend on the timeline between exposure and documented harm. PML can develop months to years after starting Tysabri, and symptoms may initially be subtle, leading to delayed diagnosis. The statute of limitations for personal injury claims in Florida is generally two years from the date the injury was discovered or should have been discovered. This means that the clock starts ticking when the patient or a reasonable person would have become aware of the link between Tysabri and their PML diagnosis. Given the progressive nature of PML, early symptoms may be mistaken for multiple sclerosis relapse, potentially delaying recognition of the true cause. For patients considering a settlement, key factors include the severity of disability, medical expenses, lost income, and the strength of evidence linking the specific case to Tysabri. The presence of anti-JCV antibodies and duration of therapy are documented risk factors that can support causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, the requirement for prescribers to monitor patients and report PML cases creates a documented trail that can be used to establish the timeline of exposure and harm. Patients who developed PML after two or more years of Tysabri treatment, especially if they had anti-JCV antibodies, have a stronger basis for claiming that the risk was foreseeable and that warnings should have been heeded. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML through a well-understood mechanism, and the drug's labeling includes specific risk factors and monitoring requirements. For Florida patients, the statute of limitations for filing a claim is typically two years from discovery of the injury, making timely legal consultation critical. Settlement considerations should account for the severity of PML, the documented risk factors present in the patient's history, and the adequacy of warnings provided by the prescriber. Patients and their families should seek legal advice promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For PML linked to Tysabri, this means the clock starts when the patient or a reasonable person would have become aware of the connection between the drug and the diagnosis.

What are the key risk factors for developing PML while on Tysabri?

Three main risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are documented in the FDA-approved labeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri FDA Labeling (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.